Esophageal and Gastroesophageal Junction Carcinoma

Esophageal and Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 460
Recruiting: 254
Ph III recruiting: 40
Growth YoY: +36.1%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (120)

clinicaltrialsPublishedShowing 151–200 of 279 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07311408	SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554)	recruiting	Phase 2	40	Jingdong ZhangOTHER	1	Dec 31, 2025	clinicaltrials
NCT07312578	Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma	enrolling by invitation	Phase 2	48	Peking UniversityOTHER	1	Dec 31, 2025	clinicaltrials